MI2026 – Mike Luo

Title:
Mike Luo, a pioneer in flow cytometry in China: 4a Bio and ProImmune walk side by side, empowering life sciences

Abstract:
Suzhou 4a Biotechnology Co., Ltd., formerly known as Beijing 4a Biotechnology Co., Ltd., was founded in 2009. It is a national high-tech enterprise integrating biopharmaceutical product research and development, large-scale production, marketing, and professional technical services. After more than a decade of continuous development and technological accumulation, the company has built a complete technology platform with flow cytometry technology as its core feature, creating a rich product line covering immune detection, clinical diagnosis, and scientific research applications. Its business scope comprehensively covers three core areas: basic research in life sciences, innovative drug development, and in vitro diagnostics (IVD).

As a pioneer in the Chinese immunological research market, Suzhou 4a Biotechnology has established a long-term strategic partnership with ProImmune, a leading global provider of immunology solutions. For over two decades, the two companies have collaborated to deeply empower domestic research institutions, pharmaceutical companies, and clinical laboratories with professional products and high-quality services. Together, they are promoting the application of key technologies such as flow cytometry, antigen-specific T-cell analysis, and immune monitoring in the fields of oncology, vaccine development, infectious diseases, and autoimmune diseases, continuously injecting momentum into the high-quality development of China’s life science and scientific research reagent industry.

Biography:
Luo Min holds a Bachelor’s degree in Biology from Anhui University, a Master’s degree in Biology from Peking University, and a PhD from the Institute of Genetics, Fudan University. He is a leading entrepreneurial talent in Suzhou High-tech Zone and a key pioneer in China’s flow cytometry technology field.

He possesses over 30 years of experience in the market and industry of biological reagents and life sciences. In 1992, he founded Shenzhen Jingmei Biotechnology, successfully developing and launching the TORCH series of diagnostic kits, filling a gap in the domestic market. He led the company to obtain product distribution rights for over 100 domestic and international biotechnology companies worldwide, including exclusive distribution rights in China for Genzyme (a leading global supplier of cytokine reagents at the time) and PharMingen (the world’s largest independent supplier of flow cytometry monoclonal antibody reagents at the time), laying the early foundation for the development of the domestic flow cytometry and immunoassay reagent market.